Q1 Earnings Forecast for CATX Issued By Lifesci Capital

Perspective Therapeutics, Inc. (NYSE:CATX) – Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Perspective Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Lifesci Capital analyst D. Kennedy anticipates that the company will post earnings per share of ($0.28) for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Lifesci Capital also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.10) EPS.

CATX has been the subject of several other reports. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price for the company. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX opened at $2.20 on Monday. The company’s fifty day moving average price is $2.94 and its 200-day moving average price is $6.29. Perspective Therapeutics has a one year low of $2.19 and a one year high of $19.05.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares during the period. State Street Corp grew its holdings in Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares during the period. FMR LLC raised its stake in shares of Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Perspective Therapeutics by 1,302.7% during the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after purchasing an additional 44,174 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.